Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medtech

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

- PMLiVE

GW Pharma says German Sativex pricing “unacceptable”

May pull MS drug from market

- PMLiVE

The future of market access through a communications lens

Communications will play a pivotal role in helping pharma to define the value agenda

EISAI

Eisai “appalled” at decision not to recommend Fycompa in Germany

Regulator says pharma company filed inadequate comparison data for its epilepsy drug

- PMLiVE

SMC approves Eliquis, restricts use of Rienso

Pfizer-BMS' anticoagulant backed but Takeda's drug given second-line recommendation

- PMLiVE

Sanofi’s Marcoux joins National Public Relations

He will lead the agency's healthcare communications practice

Sanofi’s Steve Oldfield to co-chair UK medicines access group

Takes over from UCB’s Matthew Speers in joint government/industry group

- PMLiVE

Access Partnership expands its senior team

Kevin Mayo joins as VP in the US and Pascal King as global director in London

- PMLiVE

NICE metrics flawed and should not be used, says EU study

ECHOUTCOME criticises used of quality adjusted life years in HTAs

- PMLiVE

Scotland launches £21m fund for rare conditions

Will pay for orphan medicines not recommended by the SMC

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

- PMLiVE

Pharma ‘influencing Polish drug market’

Leads to recommendations for expensive and ineffective medicines says study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links